Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I can't understand how this is staying under the radar, given the potential here and the genomic sequencing that must be in uber demand right now-Dont know a company who does just that in the uk, Europe and USA do you?
Agree patience is key and also that cash position should have risen substantially.
Cellular pathology and genetic sequencing a huge opportunities in the future and if the current COVID testing windfall allowed them to acquire business in those areas it paints a rosy picture both short and long-term.
Just registered for updates direct to my email & got a personal email from a director within 24hrs
Nice touch…..PS looking at the huge growth in PCR tests completed in the half year statement
that cash position of 17m should be significantly improved .
Nope thats all correct .All i can say is welcome to the AIM market.But remember cream always rises patience required.
PCR testing back for travel and we have the best value day 2 test on the market according to Which?
£110m MC, below IPO. But with sales growing to approx. £85m this year from £50m. With a growing cash war chest, last noted at £17m.
So..... Am I missing something obvious?
Why is this so under the radar/unloved?
From the boss in the interims:
"We expect the focus of acquisitions to be similar or complementary businesses most likely relevant to the Healthcare Diagnostics (with cellular pathology and precision medicine targets being of particular interest) and Genomics business units."
SBI will use the testing profits to push the business on.
Will we get an RNS we had one when the government dropped PCR tests now they are coming back
be good to get an update to know if the company has kept the capacity for testing at the previous high levels…
Nicola sturgeon advises Johnson to introduce day 2 day 8 pcr tests.
Good value is now great value with PCR tests back in force next week !
Certainly good value but value doesn’t always translate to share price
Most under the radar covid stock on the market big rerate due
Should be big jump monday. All travelers must take pcr test big money for sbi.
Somethings afoot price edging up from lows SBI recruiting methinks they must have takeover target in sight.
By whom though? Who would be in the business of buying lab services companies?
Rather than looking for aquisisions .Could well be on the radar itself with all that cash sloshing around.
apologies but having looked at their Sept statement Ebitda was only just over 30% in the first half of the year ( I had previously read that covid ebitda was about 40%) so this may be lower because maybe the NHS tariff is less than private price. With that we could adjust full year EBITDA at £150m revenue to £45m. That would give them an EV to Ebidta ratio of around around 2.2 and about £50 m in the bank at the end of the year.
That is true but they were only doing about £20m in revenue from their 3 other businesses in 2019. Now they are a quality company and provide excellent service and they only started Covid testing in May 2020. They did £51m in revenue in 2020 in total and £37m in the first 6 months of 2021 and it looks as if their Covid testing is significantly more in the second half of 2021. They said in their half year report that they were doing 14,000 covid pcr tests per day in September and now he is saying they are doing 20k per day in October so my previous average estimates are probably way down on current revenues because that is £500k per day in Sept and £800k per day in October and with this third wave it looks like the NHS demand they have is not decreasing any time soon. So lets say they have on average £500k per day Covid revenue in the second half of 2021 that would be £90m in covid revenue in the second half of the year and £10m other revenue, - full year revenue of around £140 to £150m about £55m to £60m in full year Ebitda 2021. take off tax etc that's about another £40m in the bank so they end up with around £60m in the bank at the end of the year and probably continuing high numbers of testing well into 2022. At 130p share price (£100m market cap) that is essentially giving no value to the covid/ID business into the future and valuing the pathology/refrigeration and NGS business at 2x revenue (about £40m). it's very much a value play but until they post the numbers in January I don't think the share price moves much. Now they are in the process of setting up the lab in San Diego and they were estimating an extra 2000 pcr tests per day from that lab, but they were waiting on final USA approval (?FDA approval) to get that lab up and running which has been in the pipeline for a long time. So who knows. Certainly, if I had £100m in my back pocket, it would seem like an absolute bargain. You'd basically get your money back in revenue back in less than a year with a 40% Ebitda and get the whole non covid business thrown in.
Sbi's day will come its much more than a covid stock fundementals will out eventually.
Basically, the company is making lots of cash and have £20m in the bank, no debt and a thriving covid business with much smaller pathology, pharma refrigeration, and genomics businesses. The market cap of the company is around £100m. Jay mentioned in the latest interview that they have been doing 20,000 covid pcr tests per day. I think that sounds an awful lot since they were only doing a third of that in the summer. however i believe they got a big NHS request to do testing for them a couple of months ago so maybe they are doing that number temporarily. The charge about £40 per test and have an Ebitda of around 40% per test. Even if they were doing say 10,000 per day that is £400k in revenue per day which seems incredible. That is £12m in revenue per month and about £5m per month in Ebitda which means that for covid alone at 10k test per day they are making £140m in revenue per year. Now i don't think they do 10k test per day but even if they do 5k on average over the past months and into the next 6 months then we are still looking at £70m per year in revenue from covid alone. The market is basically not giving them even 1x revenue in valuation. The yearly revenue for the company is going to be well north of the market cap. The need acguire a business that has decent profit margins.
Whats going on here, SBI confirmed as provider of day 2 lateral flow tests so why isn't this budging?
Have I missed a critical key ingredient, is this company going bust or something?
NCYT is up 12% on speculation, SBI are actually listed on the website and you can see the products for sale on provider websites???
Have I got the right company or BB?
The largest shareholder is restructuring its shareholding and I believe, floating in its own right
Sorry read 15 mill 1/5th of company
Please enlighten me 20mill shares just changed hands almost a third of the company?
Only have a small holding here, and of course I'm down. Time to sell or top up.
Topped up, still small. Seems to me the bad news is likely all in the price now. And sentiment is awful - just read this board! All highly scientific!
On va voir - we will see.....
Good spot Fonda. I too follow you as my investment in this company has been shocking to say the least. Sometimes research is just that, it doesn't mean i've researched very well.